Download PDF
Int J Sports Med 2000; 21(3): 225-227
DOI: 10.1055/s-2000-304
Orthopedics and Clinical Science
Georg Thieme Verlag Stuttgart ·New York

Increased Premature Mortality of Competitive Powerlifters Suspected to Have Used Anabolic Agents

M. Pärssinen1 , U. Kujala 2 , E. Vartiainen 3 , S. Sarna 4 , T. Seppälä1
  • 1 National Public Health Institute, Laboratory of Substance Abuse
  • 2 Unit for Sports and Exercise Medicine, Institute of Biomedicine, University of Helsinki
  • 3 National Public Health Institute, Department of Epidemiology and Health Promotion
  • 4 Department of Public Health, University of Helsinki
Further Information

Publication History

Publication Date:
31 December 2000 (online)

Also available at
    Permissions and Reprints

Misuse of supraphysiological doses of anabolic steroids is claimed to have serious side effects. The aim of the study was to determine the mortality, and the cause of premature deaths among a group of subjects who are strongly suspected to have used anabolic steroids for a non-medical purpose over several years. The mortality of 62 male powerlifters placed 1st - 5th in weight series 82.5 - 125 kg in Finnish championships during 1977 - 1982 was compared with the mortality of population controls. The mortality during the 12-year follow-up was 12.9 % for the powerlifters compared to 3.1 % in the control population. By 1993 eight of 62 powerlifters and 34 of 1094 population controls had died, thus the risk of death among the powerlifters was 4.6 timer higher (95 % CI 2.04 - 10.45; p = 0.0002). The causes of premature death among the powerlifters were suicide (3), acute myocardial infarction (3), hepatic coma (1) and non-Hodgkin's lymphoma (1). These findings add to the growing amount of evidence of an association between anabolic steroid abuse and premature death, and support the view that measures to decrease AAS misuse among both competitive and amateur athletes are justified.

Key words:

anabolic steroids, doping, increased mortality, cardiovascular diseases, suicides.

References

  • 01 Alén M. Effects of self-administered, high-dose testosterone and anabolic steroids on serum hormones, lipids, enzymes and on spermatogenesis in power athletes. Jyväskylä; University of Jyväskylä 1985
    Google Scholar
  • 02 Bahrke M S, Yesalis C E, Wright J E. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids.  Sports Med. 1996;  22 367-390
    Google Scholar
  • 03 Bhasin S, Storer T W, Berman N, Callegari C, Clevenger B, Phillips J, Bunnell T J, Tricker R, Shirazi A, Casaburi R. The effects of supraphysiological doses of testosterone on muscle size and strength in normal men.  N Engl J Med. 1996;  335 1-7
    Google Scholar
  • 04 Corrigan B. Anabolic steroids and the mind.  MJA. 1996;  165 222-226
    Google Scholar
  • 05 DuRant R H, Rickert V I, Ashworth C S, Newman C, Slavens G. Use of multiple drugs among adolescents who use anabolic steroids.  N Engl J Med. 1993;  328 922-926
    Google Scholar
  • 06 Korkia P, Stimson G V. Indications of prevalence, practise and effects of anabolic steroid use in Great Britain.  Int J Sports Med. 1997;  18 557-562
    Google Scholar
  • 07 Kujala U M, Kaprio J, Taimela S, Sarna S. Prevalence of diabetes, hypertension and ischemic heart disease in former elite athletes.  Metabolism. 1994;  43 1225-1260
    Google Scholar
  • 08 Kujala U M, Kaprio J, Sarna S, Koskenvuo M. Relationship of leisure-time physical activity and mortality. The Finnish Twin Cohort.  JAMA. 1998;  279 440-444
    Google Scholar
  • 09 Magnavita N, Teofili L, Leone G. Hodgkin's lymphoma in a cyclist treated with growth hormone.  Am J Hematol. 1996;  52 65-66
    Google Scholar
  • 10 Melchert R B, Welder A A. Cardiovascular effects of androgenic-anabolic steroids.  Med Sci Sports Exec. 1995;  27 1252-1262
    PubMedGoogle Scholar
  • 11 Middleman A B, Faulkner A H, Woods E R, Emans S J, DuRant R H. High-risk behaviors among high school students in Massachusetts who use anabolic steroids.  Pediatrics. 1995;  96 268-272
    PubMedGoogle Scholar
  • 12 Morris J N, Everitt M G, Pollard R, Chave S PW. Vigorous exercise in leisure-time: Protection against coronary heart disease.  Lancet. 1980;  2 1207-1210
    PubMedGoogle Scholar
  • 13 Nieminen M S, Rämö M P, Viitasalo M, Heikkilä P, Karjalainen J, Mäntysaari M . et al . Serious cardiovascular side effects of large doses of anabolic steroids in weight lifters.  Eur Heart J. 1996;  17 1576-1583
    CrossrefPubMedGoogle Scholar
  • 14 Paffenbarger R S Jr, Hyde R T, Wing A L, Lee I-M, Jung D L, Kambert J B. The association of changes in physical-activity level and other lifestyle characteristics with mortality among men.  N Engl J Med. 1993;  328 538-545
    CrossrefPubMedGoogle Scholar
  • 15 Sarna S, Sahi T, Koskenvuo M, Kaprio J. Increased life expectancy of world class male athletes.  Med Sci Sports Exec. 1993;  25 237-244
    PubMedGoogle Scholar
  • 16 Søe K L, Søe M, Gluud C. Liver pathology associated with the use of anabolic-androgenic steroids.  Liver. 1992;  12 73-79
    PubMedGoogle Scholar
  • 17 Vartiainen E, Puska P, Pekkanen J, Tuomilehto J, Jousilahti P. Changes in risk factors explain changes in mortality from ischaemic heart disease in Finland.  BMJ. 1994;  309 23-27
    PubMedGoogle Scholar
  • 18 Wilson J D. Androgen abuse by athletes.  Encocr Rev. 1988;  9 181-199
    CrossrefPubMedGoogle Scholar
  • 19 Yesalis C E, Wright J E, Bahrke M S. Epidemiological and policy issues in the measurement of the long term health effects of anabolic-androgenic steroids.  Sports Med. 1989;  8 129-138
    PubMedGoogle Scholar

MB Miia Pärssinen

National Public Health Institute Laboratory of Substance Abuse

Mannerheimintie 166 00300 Helsinki Finland

Phone: Phone:+ 358 (9) 4744 8425

Fax: Fax:+ 358 (9) 4744 8553

Email: E-mail:miia.parssinen@ktl.fi